Extracellular Vesicle (EV) Isolation & Enrichment Solutions

Extracellular vesicles (EVs) are nanoscale lipid bilayer particles actively secreted by cells. Although they lack functional nuclei and cannot replicate, EVs act as stable carriers of molecular information and have become an important component of modern liquid biopsy technologies. EVs contain a wide range of clinically relevant biomarkers and show strong potential for early disease detection and real-time treatment monitoring, particularly in oncology. However, current EV isolation and enrichment methods still face major challenges, including low efficiency, limited purity, and insufficient standardization. These limitations continue to hinder clinical translation and broader adoption. Our EV isolation and enrichment solutions address these challenges by enabling reliable biomarker analysis and supporting the development of next-generation liquid biopsy diagnostics.

Solution Overview

Application Areas

Using Supbio’s Exosome Isolation Kit (click to view product information), extracellular vesicles in the 20–140 nm size range can be efficiently isolated and enriched, with capture efficiencies exceeding 95%. The process yields high-purity, well-preserved samples, providing a strong foundation for downstream biomarker analysis. In addition, IMPMM is equipped with a nanoFCM nano-flow cytometer, enabling precise nanoparticle characterization of enriched EVs, including size distribution and absolute particle counts. Together, these capabilities provide customers with a reliable, integrated solution spanning EV isolation, enrichment, and analytical validation.

Enhanced Biomarker Performance

Improving the Performance of Established Tumor Markers

Our EV-based enrichment approach enhances the diagnostic performance of established tumor biomarkers such as CEA, CA19-9, and PSA. By improving both sensitivity and specificity, the technology enables more accurate cancer screening and differential diagnosis, supporting earlier detection, more informed clinical decision-making, and improved patient stratification.

Novel Biomarker Discovery

Unlocking Next-Generation Clinical Targets

Our platform also supports the discovery and validation of clinically relevant EV-associated biomarkers, including non-coding RNAs, phosphorylated proteins, and tumor-specific mutations. These capabilities accelerate biomarker development and clinical translation, opening new opportunities for precision diagnostics and personalized medicine.